Bladder Cancer UK Biomarker NIS
Research type
Research Study
Full title
A Retrospective Analysis of PD-L1, Additional Biomarkers, and Outcomes Among Patients with Advanced Bladder Cancer Treated with Chemotherapy
IRAS ID
210811
Contact name
Kevin Dinnell
Contact email
Sponsor organisation
AstraZeneca
Duration of Study in the UK
1 years, 1 months, 8 days
Research summary
Bladder cancer is the most common tumour of the entire urinary tract and is one of ten most commonly diagnosed cancer worldwide, with more than 430,000 new cases and 165,000 deaths per year.
It is increasingly understood that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumours.
PD-L1 is a protein expressed in a broad range of cancers, including bladder cancer. Medications inhibiting PD-L1 are being developed which could potentially be used to treat cancer, including bladder cancer, by enhancing the body’s immune system.
In other cancers, such as lung and renal cell carcinoma, there is evidence that the level of PD-L1 is linked to the likely length of survival.
By better understanding which types of cancer have high PD-L1 levels and how it may influence the course of the disease, scientists may be able to better develop medications used to treat these cancers.
This study will utilize past data and tumour biopsy samples that where obtained from patients who previously participated in a study with advanced bladder cancer.
The archived tumour tissue samples will be tested primarily for PD-L1 levels along with other biomarkers.
Biomarkers are used in two primary ways
1) To help diagnose conditions, ie cancer and which type of cancer a patient may have
2) To help doctors decide which is the best treatment to give patient’s and then predict how well a patient will respond to that treatment.
The main aim of this study will be to determine the overall survival in the patients with high amounts of PD-L1 compared to survival in patients with low or no amounts of PD-L1.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
16/YH/0356
Date of REC Opinion
16 Aug 2016
REC opinion
Favourable Opinion